Page 9 - Bharat Biotech

Bharat Biotech's Covaxin gets expert panel's nod for children above 2 years

First Covid-19 vaccine in the world for children this young

Awaiting regulatory nod to launch Covaxin for children: Bharat Biotech

The expert panel of India's Central Drug Authority has recommended granting emergency use authorisation to Bharat Biotech's Covaxin for children in the 2 to 18 years age group with certain conditions.

Bharat Biotech submits clinical trial data for paediatric vaccine to DCGI

The vaccine maker added that Covaxin is the first Covid-19 vaccine to be tested in the 2-6-year age group

WHO technical advisory group to take call on Covaxin EUL next week

Vaccine maker presented data before SAGE working group on Tuesday

Scientists' body expresses concern over WHO not granting EUL for Covaxin

A national network of scientists, AIPSN, has expressed concern over the World Health Organisation not granting emergency use listing for ICMR-Bharat Biotech's Covaxin.

Decision on Bharat Biotech's Covaxin EUL in October, says WHO

A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its Covaxin COVID-19 vaccine will be made in October, the World Health Organisation has said

Diligently working with WHO to obtain EUL for Covaxin: Bharat Biotech

The vaccine maker said it will make on announcement to indicate the availability of regulatory approval at an appropriate time

Top headlines: PM Modi reaches New York, FinMin withdraws spending curbs

Business Standard brings you the top headlines on Saturday

Booster dose: Bharat Biotech's nasal vaccine may be used with Covaxin

The idea is to see which combination induces better and long-lasting immune response

Bharat Biotech injects pace into Covid-19 vaccine Covaxin supply

Constraints on the availability of India's first indigenous Covid-19 vaccine could end soon

Bharat Biotech likely to start manufacturing Covaxin at Pune plant soon

Animal vaccine maker Hester Biosciences, on the other hand, is setting up a greenfield BSL-3 facility in Gujarat to make Covaxin

Paediatric Covaxin: Bharat Biotech completes phase 2/3 trials of vaccine

Bharat Biotech has completed Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI

WHO Experts' Group to take a call on EUL for Covaxin on October 6

The Strategic Advisory Group of Experts on Immunization of the WHO would be meeting in October to make its recommendations on Bharat Biotech's COVID-19 vaccine Covaxin on Emergency Use Listing

WHO emergency use authorisation to Covaxin delayed till October 5

World Health Organisation's (WHO) approval for the emergency use authorisation to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.

Bharat Biotech awaits feedback from WHO for Covaxin emergency use

: Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine Covaxin to the World health organisation for Emergency Use Listing (EUL) and is awaiting feedback from the global health watchdog. The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is yet "to be confirmed," according to the update available on WHO website. "#COVAXIN clinical trial data was fully compiled & available in June 2021. All Data submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback," Bharat Biotech tweeted. As a responsible manufacturer with past approvals for its other vaccines, the company said it would not find it appropriate to speculate or comment on approval process and its timelines, it further said. "We are continuing to work diligently on obtaining WHO EUL at the earliest, the .

Phase 2 trials begin for India's first intranasal vaccine against Covid-19

The phase 2 trials of India's first intranasal vaccine against Covid, being developed by Bharat Biotech in collaboration with Washington University School of Medicine, have commenced in Kanpur

First commercial batch of Covaxin released from Bharat Biotech's new plant

The first commercial batch of Covaxin was released on Sunday from the new plant of Bharat Biotech at Ankleshwar in Gujarat's Bharuch district by Union Health Minister Mansukh Mandaviya

Bharat Biotech scouts international Covid-19 vaccine partners

Bharat Biotech said it was exploring opportunities with its international partners who have expertise in commercial-scale manufacturing of inactivated viral vaccines.

Johnson & Johnson seeks nod for Covid vaccine trial on adolescents

To achieve herd immunity, studies have to be done on children, pharma major says

Bharat Biotech's nasal Covid-19 vaccine advances into next stage of trials

Early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be well tolerated